KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.

J Clin Oncol · 2026-Jan-20 · PMID 41365333

Panel C提取完成待 EXE 对齐验证

OS

FIG 2. Kaplan-Meier analysis of (A) DFS, (B) DDFS, and (C) OS in ITT population. Stratified HRs and its 95% CI were reported with their corresponding stratified Log-rank P value. Cb, carboplatin; DFS, disease-free survival; DDFS, distant DFS; EC-T, epirubicin plus cyclophosphamide followed by taxanes; EC-TCb, EC-T plus carboplatin; HR, hazard ratio; ITT, intention-to-treat; OS, overall survival.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.87
质量通过是
预期曲线2
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证22026-07-18T19:31:39+00:00